BridgeBio Pharma Price to Book Ratio 2018-2024 | BBIO

Historical price to book ratio values for BridgeBio Pharma (BBIO) over the last 10 years. The current price to book ratio for BridgeBio Pharma as of November 01, 2024 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

BridgeBio Pharma Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2024-11-01 25.48 0.00
2024-06-30 25.33 $-5.75 -4.40
2024-03-31 30.92 $-5.54 -5.58
2023-12-31 40.37 $-7.67 -5.26
2023-09-30 26.37 $-6.86 -3.84
2023-06-30 17.20 $-8.36 -2.06
2023-03-31 16.58 $-7.56 -2.19
2022-12-31 7.62 $-8.25 -0.92
2022-09-30 9.94 $-7.55 -1.32
2022-06-30 9.08 $-6.84 -1.33
2022-03-31 10.15 $-7.05 -1.44
2021-12-31 16.68 $-5.88 -2.83
2021-09-30 46.87 $-5.02 -9.33
2021-06-30 60.96 $-3.06 -19.94
2021-03-31 61.60 $-2.61 -23.59
2020-12-31 71.11 $0.86 82.22
2020-09-30 37.52 $1.76 21.30
2020-06-30 32.61 $2.66 12.24
2020-03-31 29.00 $3.70 7.84
2019-12-31 35.05 $3.83 9.15
2019-06-30 26.97 0.00
2019-09-30 21.47 $4.45 4.83
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.791B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00